TriangleEribulin (NCT05570253)
Eribulin trial for Breast Cancer (NCT05570253). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced triple-negative breast cancer and metabolic dysfunction, with no more than two prior advanced-disease treatment lines. Type-one, insulin-dependent or uncontrolled diabetes is excluded.
The idea: add evexomostat to eribulin chemotherapy. Evexomostat blocks MetAP2, an enzyme involved in tumor growth and blood-vessel formation. After a safety group, random assignment compares evexomostat injections with placebo; both groups receive eribulin infusions. Researchers primarily measure insulin resistance, and also assess tumor responses and safety.
This phase 2 study plans 55 patients. Memorial Sloan Kettering sponsors it; ten US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.